

Mission: Truvitech's mission is to expedite the discovery of new drugs and make them better targeted and more effective.

Problem: Identification of quality drug targets using existing technologies (genetic association studies, omics, siRNA/CRISPR) remains rate limiting, costly, and error prone. This can slow down drug development efforts by years or even decades.

Solution: idTRAX (Identification of Drug Targets and Anti-targets by Cellular and Molecular Cross-referencing), a patent-pending platform technology that uses a unique combination of proprietary chemical probes, cellular disease models, and machine learning to discover drug targets with unprecedented speed and efficiency. Our technology had great success in finding targets for nerve regeneration, cancer, infectious disease, and neuroprotection.

Key & Unique Benefits:

- Cuts the time for drug target identification (5-10 years to 3-6 months)
- Insensitive to gaps in biological knowledge due to the direct and empirical nature of the approach
- 100% of identified targets are druggable
- Identifies synergistic targets
- Identifies off-targets that must be avoided to achieve maximum therapeutic efficacy
- Works even for polygenic diseases, as well as diseases with no clear genetic driver

Business Model: We will develop drug candidates at Truvitech using the idTRAX technology. We will also offer idTRAX as a service.

Revenue streams:

- 1- Drug candidate out-licensing
- 2- idTRAX services/licenses

We are presently focused on cancer and disorders of the central nervous system, but we have strong evidence that the technology is applicable to other therapeutic areas, including rare diseases.

Why Us: We are an interdisciplinary team of highly motivated scientists with complementary expertise and a vision to revolutionize drug discovery. Truvitech is the vehicle for this vision. We are committed to making idTRAX's paradigm shifting technology a commercial reality. We have worked relentlessly for the past 6 years and demonstrated both the promise and the feasibility of our vision.

Cofounders:

Vance Lemmon, Ph.D: Professor at the University of Miami with over 15 years' experience in phenotypic screening, assay development, and big data science. PI or Co-PI on over 23M in NIH grants and Co-I on an additional 25M in NIH grants

Hassan Al-Ali, Ph.D: Assistant Professor at the University of Miami with extensive knowledge in assay development, screening, and the application of informatics and machine learning to drug discovery.

Competition: Biotechnology companies developing and implementing target identification platforms. These companies rely on one or more target identification technologies, including: genetic disease association, genomic or transcriptomic data, *in vitro* gene manipulation, proteomics. Table below shows idTRAX's competitive analysis vs other technologies and approaches that are currently on the market.

	TruviTech	GeneScript	Charles River	Creative Biolabs	Bioneer	Hybergeneics	Evotec	Intomics
Works for polygenic diseases	✓	✓		✓			✓	✓
Works for diseases with no clear genetic driver	✓							
Targets are readily druggable	✓							
Identifies efficacy anti-targets	✓							
Low false positive/negative rates	✓							
Identifies synergistic targets	✓							
Directly queries mammalian/human genes	✓	✓	✓	✓			✓	✓
Insensitive to gaps in biological knowledge	✓		✓		✓	✓	✓	
Does not require an existing hit compound	✓	✓	✓				✓	✓

Financials: Raised \$300K in NIH grants and founder contributions. Completed proof-of-concept studies, design of idTRAX platform, and patent submission. Identified a novel drug target for diffuse large B-cell lymphoma (DLBCL). Additional funding of \$10 million will enable the completion of idTRAX platform development and the creation of a DLBCL drug candidate. A positive cashflow of \$152M is anticipated by year 7, with breakeven point in year 4.

In 2 years: Truvitech completes the development of idTRAX and deploys it in internal and external campaigns. First IND-ready drug candidate is created (DLBCL).

In 5 years: 2 drugs in clinical trials (partners or licensees), 3 in preclinical (Truvitech), 5 in research stage (Truvitech).

In 10 years: Truvitech is a leader in the early-stage drug discovery and partners with major pharmaceutical companies to bring new drugs to the market faster than ever before. Two drugs already on the market.